The study showed lower reoperation rates for the Mobi-C and better mean neck disability improvement through four years.
Hyun Bae, MD, medical director and director of spine education at Cedars-Sinai in Los Angeles, presented the data earlier this month at the North American Spine Society annual meeting.
The Mobi-C is the first cervical disc replacement device approved by the FDA for both one- and two-level indications.
More Articles on Devices:
K2M, Amedica Reach European Distribution Agreement for Biomaterial Spinal Fusion Devices
Zimmer Holdings Reports Decreased Earnings, Spine Sales in Q3
15 New Spine, Orthopedic Device Launches & Releases
